Skip to main content

Table 4 Mean difference (and 95% CI) from Baseline to 3 months (T0-T3), Baseline to 6 months (T6-T0) and 3 months to 6 months (T6-T3) within allocated group and between groups for full sample

From: Effectiveness of Wellbeing Intervention for Chronic Kidney Disease (WICKD): results of a randomised controlled trial

Measure

Timepoint

ISS

HepB/DSS

TAU/DSS

ISS vs HepB/DSS

ISS vs TAU/DSS

HepB/DSS vs TAU/DSS

K10

T3-T0

0.7 (−1.4,2.8)

−2.5 (− 4.6,-0.5)*

0.4 (− 2.4,3.3)

3.2 (0.3,6.1)*

0.3 (− 3.2,3.8)

− 2.9 (− 6.4,0.6)

T6-T0

− 1.0 (− 3.0,1.1)

− 3.6 (− 5.7,-1.5)**

−0.8 (− 3.6,2.1)

2.6 (− 0.3,5.6)

− 0.2 (− 3.7,3.4)

−2.8 (− 3.3,0.7)

T6-T3

− 1.6 (− 3.8,0.5)

− 1.1 (− 3.2,1.0)

− 1.2 (− 4.1,1.7)

−0.6 (− 3.5,2.4)

− 0.4 (− 4.0,3.1)

0.1 (− 3.5,3.7)

PHQ-9

T3-T0

− 0.02 (− 3.2,0.4)

−1.6 (− 2.9,-0.3)*

0.8 (− 1.0,2.7)

1.4 (− 0.4,3.2)

−1.0 (− 3.3,1.2)

− 2.4 (− 4.7,-0.2)

T6-T0

−0.7 (−2.1,0.6)

− 1.4 (− 2.8,-0.1)*

0.3 (− 1.6,2.1)

0.7 (− 1.2,2.6)

−1.0 (− 3.2,1.3)

−1.7 (− 3.9,0.5)

T6-T3

−0.5 (− 1.9,0.8)

0.1 (− 1.2,1.5)

−0.6 (− 2.4,1.2)

−0.7 (− 2.6,1.2)

0.1 (− 2.2,2.3)

0.7 (− 1.5,3.0)

  1. *difference is significant at p< 0.05
  2. ** difference is significant at p< 0.001